Broadcom heads into the final days of July having done something its semiconductor peers conspicuously failed to do this week — hold its ground.
The price story is modest but meaningful in context. AVGO closed Tuesday at $380.91, down just 1.4% on the week and 0.6% on the day. That compares to a brutal peer tape: ARM dropped 15.5% on the week, AMD fell 16.5%, and MU shed 15.5%. NVDA was the lone holdout, down a comparatively mild 5%. Against that backdrop, Broadcom's weekly decline looks less like weakness and more like relative resilience — the stock is still 20% below its pre-earnings close of $479.23, but the $360 floor established in early July continues to hold.
The short interest story has quietly shifted. Bears have trimmed for the first time in weeks. Short interest has fallen from roughly 70.8 million shares on July 20 to 68.9 million by July 28 — a drop of about 2.7% on the week — bringing the float short down to 1.46%. That is still elevated compared to the 1.10%–1.16% range that prevailed through most of June, but the directional change is notable after ten sessions of near-stasis flagged in prior reports. The lending market offers no constraint on either side: availability is essentially unlimited, and cost to borrow runs at just 0.33%, barely changed from last week. The ORTEX short score of 30.9 has drifted slightly lower through the week, consistent with a modest unwinding rather than any aggressive repositioning.
Options positioning is close to neutral. The put/call ratio is running at 1.08, fractionally above its 20-day average of 1.06 and with a z-score of just 0.54 — well within normal range. This is not a market leaning hard either way through derivatives. The 52-week range runs from 0.89 to 1.23, and the current reading sits comfortably in the middle, suggesting options traders are neither building downside protection nor aggressively reaching for upside.
The Street remains firmly constructive, but the gap between analyst targets and the current price is striking. The consensus mean target is $525, implying 38% upside from current levels — yet the most recent analyst move was a downgrade to Hold from Erste Group on July 7. The bulk of post-earnings analyst activity in early June was bullish: JPMorgan raised its target to $580, BofA lifted to $530, and several other houses bumped targets into the $500–$550 range after the Q2 print. That enthusiasm has not translated into price recovery. The bull case centres on AI semiconductor demand and the VMware integration delivering durable revenue, while bears point to guide quality concerns — second-half growth implied meaningfully below first-half levels — and the structural premium already embedded in the valuation. At a forward PE of 23.6 and EV/EBITDA of 18.9, the multiple has compressed somewhat over the past month, which could begin to attract buyers who found the summer highs too rich.
Insider activity adds a note of caution. The Chief Legal Officer, Mark Brazeal, sold 75,000 shares across three tranches in late June and early July at prices ranging from $379 to $401 — totalling just over $29 million. Chairman Henry Samueli sold approximately 146,000 shares on June 24 alone, bringing in roughly $56 million. Net insider selling over the past 90 days runs to around $281 million. These look like systematic planned-sale programmes rather than conviction calls, but the volume is not trivial against a stock that has struggled to recover.
The next hard catalyst is the Q3 earnings report on September 3. With two consecutive post-earnings declines of 13% and 19.5% in the history, and the stock still trading well below where those drops began, the setup heading into that print is what matters most to watch over the coming weeks.
See the live data behind this article on ORTEX.
Open AVGO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
